Atara Biotherapeutics Inc (NASDAQ:ATRA) saw unusually large options trading activity on Tuesday. Investors acquired 1,007 call options on the company. This is an increase of 1,551% compared to the average volume of 61 call options.

Shares of NASDAQ ATRA opened at $14.11 on Wednesday. The company has a market capitalization of $715.52 million, a price-to-earnings ratio of -2.68 and a beta of 2.08. Atara Biotherapeutics has a 12-month low of $11.89 and a 12-month high of $43.95. The business’s fifty day moving average is $16.23. The company has a debt-to-equity ratio of 0.05, a quick ratio of 9.96 and a current ratio of 9.96.

Atara Biotherapeutics (NASDAQ:ATRA) last issued its earnings results on Thursday, August 8th. The biotechnology company reported ($1.60) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.45) by ($0.15). As a group, equities analysts anticipate that Atara Biotherapeutics will post -5.54 EPS for the current year.

ATRA has been the topic of a number of research reports. ValuEngine lowered shares of Atara Biotherapeutics from a “buy” rating to a “hold” rating in a research note on Friday, May 17th. Mizuho reiterated a “buy” rating and issued a $62.00 price target on shares of Atara Biotherapeutics in a research note on Thursday, May 9th. William Blair reiterated a “buy” rating on shares of Atara Biotherapeutics in a research note on Thursday, May 16th. Canaccord Genuity reiterated a “buy” rating and issued a $70.00 price target on shares of Atara Biotherapeutics in a research note on Monday, July 1st. Finally, BidaskClub upgraded shares of Atara Biotherapeutics from a “strong sell” rating to a “sell” rating in a research note on Tuesday. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and seven have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $41.33.

In other news, CEO Isaac E. Ciechanover sold 5,850 shares of the business’s stock in a transaction dated Thursday, May 30th. The shares were sold at an average price of $23.09, for a total transaction of $135,076.50. Following the transaction, the chief executive officer now directly owns 332,243 shares in the company, valued at approximately $7,671,490.87. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Eric Dobmeier purchased 2,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 27th. The stock was bought at an average price of $19.50 per share, for a total transaction of $39,000.00. Following the purchase, the director now owns 16,000 shares in the company, valued at approximately $312,000. The disclosure for this purchase can be found here. Company insiders own 7.00% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the business. NumerixS Investment Technologies Inc bought a new position in shares of Atara Biotherapeutics in the second quarter valued at approximately $272,000. BlackRock Inc. boosted its position in shares of Atara Biotherapeutics by 10.2% in the second quarter. BlackRock Inc. now owns 3,841,451 shares of the biotechnology company’s stock valued at $77,252,000 after acquiring an additional 357,026 shares during the period. Baupost Group LLC MA boosted its position in shares of Atara Biotherapeutics by 9.7% in the second quarter. Baupost Group LLC MA now owns 7,000,000 shares of the biotechnology company’s stock valued at $140,770,000 after acquiring an additional 619,481 shares during the period. Virtus ETF Advisers LLC bought a new position in shares of Atara Biotherapeutics in the second quarter valued at approximately $245,000. Finally, Public Employees Retirement System of Ohio boosted its position in shares of Atara Biotherapeutics by 29.2% in the second quarter. Public Employees Retirement System of Ohio now owns 25,765 shares of the biotechnology company’s stock valued at $518,000 after acquiring an additional 5,823 shares during the period.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.

Featured Article: What are the most popular ETFs

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.